Of note, olaparib represents the most cost-effective [295] PARP inhibitor, and the olaparib plus bevacizumab regimen achieved a dramatic improvement in PFS in ovarian cancer patients with BRCA mutations (37.2 months) and without BRCA mutations (28.1 months) compared to that with placebo plus bevacizumab (17.7 and 16.6 months, respectively) [296]. Here, PARP1 is linked to ovarian cancer.